Indiana University
MAPS & DIRECTIONS Maps FIND PEOPLE Find People

Research Trials

The Efficacy and Safety of a Selective Estrogen Receptor Beta agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated with Schizophrenia

PI: Alan Breier, MD

 

Click here to view official details about this study!

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

PI: Alan Breier, MD

 

Click here to view official details about this study!

 


Safety and Efficacy of Fingolimod in Schizophrenia Patients who have Suboptimal Responses to Antipsychotic Drug Treatment

PI: Alan Breier, MD.



 

 


 

-A Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period.

PI: Alan Breier, MD.

Click here to view official details about this study



-A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.

PI: Alan Breier, MD.

Click here to view offial details about this study



-Indiana University Psychotic Disorders Program Genetic Repository and Bank

PI: Alan Breier, MD.


Current Trials - Non-Enrolling


 

-An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia

PI: Alan Breier, MD.


 

-A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

PI: Alan Breier, M.D.

 


-A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia

 

PI: Alexander Radnovich, M.D., Ph.D.

 


-A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia

 

PI: Alan Breier, M.D.

 


 


Previous Trials



-A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with Standard of Care Compared to Placebo Combined with Standard of Care in the Treatment of Patients with Prominent Negative Symptoms of Schizophrenia (H8Y-MC-HBCO)

PI: Emily Liffick, MD.


 

 

 

-A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia

PI: Emily Liffick, M.D.


 

 

 

-A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia

PI: Alan Breier, M.D.


 

 

 

-A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse

PI: Alan Breier, M.D.


If you are interested in research at IUPDP, please visit our contact page or call the study line at (317) 274-0474.


Dont forget to Like us on Facebook!  ZA102637861.GIF

Instagram